Sign in
MGTA Stock Price, Chart, Stats & News
Magenta Therapeutics, Inc.
Save
42.44M
Market cap
–
Current P/E
–
Forward P/E
MGTA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | -8739.34% |
Pretax margin | -7973.33% |
Net margin | -7973.33% |
Effective tax rate | – |
ROA | -30.58% |
ROE | -38.85% |
D/E | 0.00x |
Interest coverage ratio | – |
MGTA valuation
P/E | – |
P/S | 20.85x |
P/B | 0.01x |
P/CF | -0.02x |
P/FCF | -0.33x |
P/OCF | -0.02x |
PEG | 0.00x |
EV multiple | -0.53x |
About
Magenta Therapeutics, Inc. is a biotechnology firm in the clinical development stage, dedicated to advancing therapies that leverage the transformative potential of stem cell transplantation for individuals afflicted with blood cancers, genetic illnesses, and autoimmune conditions. Among its key pipeline candidates is MGTA-117, an anti-CD117 antibody. This compound specifically targets hematopoietic stem cells (HSCs) and the genetically altered stem cells implicated in acute myeloid leukemia and myelodysplastic syndromes, and is currently progressing through Phase I/II clinical trials.
Similar securities
Based on sector and market capitalization
Report issue